• news

Celaid Therapeutics will be a finalist in the "Boehringer Ingelheim Innovation Prize"!

Celaid Therapeutics has been selected as one of the eight most outstanding projects in the field of innovative medical and biotechnology in the "Boehringer Ingelheim Innovation Prize" organized by Nippon Boehringer Ingelheim Co., Ltd.. Celaid will now take the stage at the pitch contest as a finalist, which will be held on September 28, 2022.

Website: Nippon Boehringer Ingelheim Co., Ltd.


< Pitch contest >

Company/University Presentation
Celaid Therapeutics Inc. Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells for allogeneic HSCT with Hematologic malignancies
C4U Corporation NextGen CRISPR-Cas3 Gene Editing Technology
FerroptoCure Inc. Anti-cancer drug inducing “Ferroptosis”
Gap Junction Therapeutics, Inc. Development of gene therapy and drugs for hearing loss
miibio, Inc A photo-controllable gene therapy
Rebirthel Co., Ltd. Technologies for allogeneic regenerated T cell therapy derived from iPS cells
siDreaMed(tentative name) Development and commercialization of siRNAs that suppress only disease-causing genes with single nucleotide mutations.
Tohoku University(Dr. Ichiro Kawahata) Development of peptide drug for Lewy body diseases

Copyright© セレイドセラピューティクス - 細胞治療(造血幹細胞) , 2024 All Rights Reserved Powered by STINGER.